Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283726901> ?p ?o ?g. }
- W4283726901 endingPage "668" @default.
- W4283726901 startingPage "657" @default.
- W4283726901 abstract "The Phase 3 DISCOVER-1 study of guselkumab is the first randomized controlled trial to use Patient-Reported Outcomes Measurement Information System (PROMIS) measures to assess the effects of treatment on general health outcomes in patients with psoriatic arthritis (PsA). Patients (N = 381) with active PsA were randomized 1:1:1 to guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at Week 0, Week 4, then every 8 weeks (Q8W); or placebo with Week 24 crossover to guselkumab Q4W. The PROMIS-29 Profile contains four items for each of seven domains (anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and social participation) and one pain-intensity item. Raw domain scores are converted to standardized T-scores, with norms based on a US general population mean of 50 (1 standard deviation (SD) = 10). T-score changes of ≥ 5 are considered clinically meaningful. Least-squares mean PROMIS-29 T-score changes from baseline to Week 24 and Week 52 were summarized for the guselkumab and placebo groups; nominal p-values comparing results between guselkumab and placebo were calculated at Week 24 using a mixed model for repeated measures. The proportions of patients who achieved clinically meaningful improvement in PROMIS-29 T-scores were also summarized at Week 24 and Week 52; nominal p-values comparing results between guselkumab and placebo were calculated at Week 24 using the Cochran-Mantel-Haenszel test. In the DISCOVER-1 patient population, mean PROMIS-29 T-scores at baseline were ~ 1 SD worse for physical function and pain interference and were numerically worse for social participation, fatigue, and sleep disturbance compared with the US general population. At Week 24, mean PROMIS-29 T-scores improved in guselkumab-treated patients, approaching US population norms; T-scores continued to improve through Week 52. Significantly higher proportions of patients in both guselkumab treatment arms (31–52% across domains) had clinically meaningful improvements in pain interference, fatigue, physical function, sleep, and social participation at Week 24 versus placebo (all nominal p ≤ 0.05). In patients with active PsA, guselkumab treatment provided clinically meaningful reductions in fatigue and pain and improvement in physical function and social participation, as measured by the PROMIS-29 Profile. These improvements were maintained through 1 year. Registration number, NCT03162796; Submission date 19 May 2017." @default.
- W4283726901 created "2022-07-01" @default.
- W4283726901 creator A5001440423 @default.
- W4283726901 creator A5015084747 @default.
- W4283726901 creator A5016489941 @default.
- W4283726901 creator A5021293751 @default.
- W4283726901 creator A5030325032 @default.
- W4283726901 creator A5031141146 @default.
- W4283726901 creator A5034020691 @default.
- W4283726901 creator A5043615700 @default.
- W4283726901 creator A5051239558 @default.
- W4283726901 creator A5055685727 @default.
- W4283726901 creator A5064558634 @default.
- W4283726901 creator A5084697265 @default.
- W4283726901 creator A5085522760 @default.
- W4283726901 date "2022-06-30" @default.
- W4283726901 modified "2023-10-17" @default.
- W4283726901 title "Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study" @default.
- W4283726901 cites W113797418 @default.
- W4283726901 cites W1807311314 @default.
- W4283726901 cites W1902838605 @default.
- W4283726901 cites W1965986657 @default.
- W4283726901 cites W1994114414 @default.
- W4283726901 cites W2029920297 @default.
- W4283726901 cites W2056328337 @default.
- W4283726901 cites W2089468569 @default.
- W4283726901 cites W2098872863 @default.
- W4283726901 cites W2102347458 @default.
- W4283726901 cites W2138871559 @default.
- W4283726901 cites W2162420979 @default.
- W4283726901 cites W2197349645 @default.
- W4283726901 cites W2223868808 @default.
- W4283726901 cites W2290259248 @default.
- W4283726901 cites W2331762069 @default.
- W4283726901 cites W2345074738 @default.
- W4283726901 cites W2503539033 @default.
- W4283726901 cites W2514573576 @default.
- W4283726901 cites W2589998748 @default.
- W4283726901 cites W2610917967 @default.
- W4283726901 cites W2613037581 @default.
- W4283726901 cites W2616032193 @default.
- W4283726901 cites W2694363605 @default.
- W4283726901 cites W2753519820 @default.
- W4283726901 cites W2755353805 @default.
- W4283726901 cites W2773505783 @default.
- W4283726901 cites W2793808927 @default.
- W4283726901 cites W2800270183 @default.
- W4283726901 cites W2885946785 @default.
- W4283726901 cites W2908474938 @default.
- W4283726901 cites W2985548490 @default.
- W4283726901 cites W2994547995 @default.
- W4283726901 cites W3003788554 @default.
- W4283726901 cites W3004318155 @default.
- W4283726901 cites W3011285271 @default.
- W4283726901 cites W3015597783 @default.
- W4283726901 cites W3023415012 @default.
- W4283726901 cites W3027601530 @default.
- W4283726901 cites W3082579367 @default.
- W4283726901 cites W3092254846 @default.
- W4283726901 cites W3112797912 @default.
- W4283726901 cites W3123750794 @default.
- W4283726901 cites W3126609786 @default.
- W4283726901 cites W3127587557 @default.
- W4283726901 cites W3136776358 @default.
- W4283726901 cites W3182511419 @default.
- W4283726901 cites W4229060367 @default.
- W4283726901 cites W4241915332 @default.
- W4283726901 cites W4285719527 @default.
- W4283726901 doi "https://doi.org/10.1007/s40271-022-00588-6" @default.
- W4283726901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35768650" @default.
- W4283726901 hasPublicationYear "2022" @default.
- W4283726901 type Work @default.
- W4283726901 citedByCount "2" @default.
- W4283726901 countsByYear W42837269012022 @default.
- W4283726901 crossrefType "journal-article" @default.
- W4283726901 hasAuthorship W4283726901A5001440423 @default.
- W4283726901 hasAuthorship W4283726901A5015084747 @default.
- W4283726901 hasAuthorship W4283726901A5016489941 @default.
- W4283726901 hasAuthorship W4283726901A5021293751 @default.
- W4283726901 hasAuthorship W4283726901A5030325032 @default.
- W4283726901 hasAuthorship W4283726901A5031141146 @default.
- W4283726901 hasAuthorship W4283726901A5034020691 @default.
- W4283726901 hasAuthorship W4283726901A5043615700 @default.
- W4283726901 hasAuthorship W4283726901A5051239558 @default.
- W4283726901 hasAuthorship W4283726901A5055685727 @default.
- W4283726901 hasAuthorship W4283726901A5064558634 @default.
- W4283726901 hasAuthorship W4283726901A5084697265 @default.
- W4283726901 hasAuthorship W4283726901A5085522760 @default.
- W4283726901 hasBestOaLocation W42837269011 @default.
- W4283726901 hasConcept C126322002 @default.
- W4283726901 hasConcept C142724271 @default.
- W4283726901 hasConcept C168563851 @default.
- W4283726901 hasConcept C1862650 @default.
- W4283726901 hasConcept C204787440 @default.
- W4283726901 hasConcept C27081682 @default.
- W4283726901 hasConcept C2776260265 @default.
- W4283726901 hasConcept C2777077863 @default.
- W4283726901 hasConcept C2908647359 @default.